一系列四环咪唑衍生物9a,9b,9c,9d,9e,9f,9g,9h,9i,9j,9k,9l,9m,9n,9o,9p,9r,9s,9t,9v和10a,10b,10c,10d,10e,10f,从已知的三环二酮2a,2b,2c,2d开始,通过多步路线制备10g,10h。中间二苯并恶唑啉[4,5- d ]咪唑(3a,3c)和二苯并噻吩[4,5- d ]咪唑(3b,3d)被N-保护至4e ,4f和同分异构化合物5a,5b和6a,6b。异构体化合物5和6 分开了。化合物4,5,和6中C(2)的甲酰化,得到图7a,图7b,图7c,7d中,7E,7F,7克,7H,7I,7J。在最后一步中,将醛基还原,然后烷基化为两组异构的ω-二甲基氨基烷基衍生物9a,9b,9c,9d,9e,9f,9g,9h,9i,9j,9k,9l,9m,9n,9o,9p,9r,9s,9t,9v。N脱保护9i–9v生成化合物10a,10b
1,3-diaza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof
申请人:Mercep Mladen
公开号:US20050227963A1
公开(公告)日:2005-10-13
The present invention relates to 1,3-diaza-dibenzoazulene derivatives, to their pharmacologically acceptable salts and solvates, to processes and intermediates for the preparation thereof as well as to their antiinflammatory effects, especially to the inhibition of tumour necrosis factor-α (TNF-α) production and the inhibition of interleukin-1 (IL-1) production as well as to their analgetic action.
1,3-DIAZA-DIBENZOAZULENES AS INHIBITORS OF TUMOUR NECROSIS FACTOR PRODUCTION AND INTERMEDIATES FOR THE PREPARATION THEREOF
申请人:GlaxoSmithKline istrazivacki centar Zagreb d.o.o.
公开号:EP1509528B1
公开(公告)日:2008-09-24
USE OF 1,3-DIAZA-DIBENZO[e,h] AZULENES FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS
申请人:GlaxoSmithKline istrazivacki centar Zagreb d.o.o.
公开号:EP1684749B1
公开(公告)日:2007-09-05
1,3-Diaza-dibenzo[e,h]azulenes for the treatment of central nervous system diseases and disorders
申请人:Mercep Mladen
公开号:US20070129330A1
公开(公告)日:2007-06-07
The present invention relates to the use of compounds from the group of 1,3-diaza-dibenzo[e,h]azulenes and of their pharmaceutically acceptable salts and solvates for the for the use in the treatment and prevention of diseases, damages and disorders of the central nervous system (CNS) caused by disorders of the neurochemical equilibrium of biogenic amines or other neurotransmitters.